Pharmaceutical companies Novo Nordisk and Eli Lilly are moving towards oral formulations of anti-obesity medications, following the success of their injectable therapies. This decision comes as these companies seek to expand their range of treatments for people suffering from obesity.
Following a successful launch in the American market, these companies are now preparing to introduce their new products in additional countries, marking an important step in the development of solutions against obesity.
We would like to count which pages are read — with our own statistics on our own server in Frankfurt am Main. No cookies are set for that and nothing is stored on your device. We ask nevertheless before we count. Without your consent the site remains fully usable — nothing is missing.
